|
 |
|
|||||||
|
|||||||||
© 2002 by the American Diabetes Association, Inc.
Regulation of Glucose Transport and Insulin Signaling by Troglitazone or Metformin in Adipose Tissue of Type 2 Diabetic Subjects
1 VA San Diego Healthcare System and the Department of Medicine, University of California, San Diego, California
2 Quest Diagnostics, San Juan Capistrano, California
Type 2 diabetic subjects failing glyburide therapy were randomized to receive additional therapy with either metformin (2,550 mg/day) or troglitazone (600 mg/day) for 3–4 months. Biopsies of subcutaneous abdominal adipose tissue were obtained before and after therapy. Glycemic control was similar with both treatments. Metformin treatment increased insulin-stimulated whole-body glucose disposal rates by 20% (P < 0.05); the response to troglitazone was greater (44% increase, P < 0.01 vs. baseline, P < 0.05 vs. metformin). Troglitazone-treated subjects displayed a tendency toward weight gain (5 ± 2 kg, P < 0.05), increased adipocyte size, and increased serum leptin levels. Metformin-treated subjects were weight-stable, with unchanged leptin levels and reduced adipocyte size (to 84 ± 4% of control, P < 0.005). Glucose transport in isolated adipocytes from metformin-treated subjects was unaltered from pretreatment. Glucose transport in both the absence (321 ± 134% of pre-Rx, P < 0.05) and presence of insulin (418 ± 161%, P < 0.05) was elevated after troglitazone treatment. Metformin treatment had no effect on adipocyte content of GLUT1 or GLUT4 proteins. After troglitazone treatment, GLUT4 protein expression was increased twofold (202 ± 42%, P < 0.05). Insulin-stimulated serine phosphorylation of Akt was augmented after troglitazone (170 ± 34% of pre-Rx response, P < 0.05) treatment and unchanged by metformin. We conclude that the ability of troglitazone to upregulate adipocyte glucose transport, GLUT4 expression, and insulin signaling can contribute to its greater effect on whole-body glucose disposal.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Basu, P. Shah, A. Basu, B. Norby, B. Dicke, V. Chandramouli, O. Cohen, B. R. Landau, and R. A. Rizza Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes Diabetes, January 1, 2008; 57(1): 24 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ranganathan, R. Unal, I. Pokrovskaya, A. Yao-Borengasser, B. Phanavanh, B. Lecka-Czernik, N. Rasouli, and P. A. Kern The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment J. Lipid Res., November 1, 2006; 47(11): 2444 - 2450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. P. Ciaraldi, D. K. Oh, L. Christiansen, S. E. Nikoulina, A. P. S. Kong, S. Baxi, S. Mudaliar, and R. R. Henry Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E891 - E898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Collier, C. R. Bruce, A. C. Smith, G. Lopaschuk, and D. J. Dyck Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle Am J Physiol Endocrinol Metab, July 1, 2006; 291(1): E182 - E189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. M. Viljanen, K. A. Virtanen, M. J. Jarvisalo, K. Hallsten, R. Parkkola, T. Ronnemaa, F. Lonnqvist, P. Iozzo, E. Ferrannini, and P. Nuutila Rosiglitazone Treatment Increases Subcutaneous Adipose Tissue Glucose Uptake in Parallel with Perfusion in Patients with Type 2 Diabetes: A Double-Blind, Randomized Study with Metformin J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6523 - 6528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-Y. Lin, T. Gurlo, L. Haataja, W. A. Hsueh, and P. C. Butler Activation of Peroxisome Proliferator-Activated Receptor-{gamma} by Rosiglitazone Protects Human Islet Cells against Human Islet Amyloid Polypeptide Toxicity by a Phosphatidylinositol 3'-Kinase-Dependent Pathway J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6678 - 6686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Klein, S. Westphal, D. Kraus, B. Meier, N. Perwitz, V. Ott, M. Fasshauer, and H H. Klein Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes J. Endocrinol., November 1, 2004; 183(2): 299 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bogacka, H. Xie, G. A. Bray, and S. R. Smith The Effect of Pioglitazone on Peroxisome Proliferator-Activated Receptor-{gamma} Target Genes Related to Lipid Storage In Vivo Diabetes Care, July 1, 2004; 27(7): 1660 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bays, L. Mandarino, and R. A. DeFronzo Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478. [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Salpeter, E. Greyber, G. A. Pasternak, and E. E. Salpeter Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis Arch Intern Med, November 24, 2003; 163(21): 2594 - 2602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Pavo, G. Jermendy, T. T. Varkonyi, Z. Kerenyi, A. Gyimesi, S. Shoustov, M. Shestakova, M. Herz, D. Johns, B. J. Schluchter, et al. Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1637 - 1645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. R. Aroda and R. R. Henry Thiazolidinediones: Potential Link Between Insulin Resistance and Cardiovascular Disease Diabetes Spectr, April 1, 2003; 16(2): 120 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Phillips, T. P. Ciaraldi, A. P.S. Kong, R. Bandukwala, V. Aroda, L. Carter, S. Baxi, S. R. Mudaliar, and R. R. Henry Modulation of Circulating and Adipose Tissue Adiponectin Levels by Antidiabetic Therapy Diabetes, March 1, 2003; 52(3): 667 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Virtanen, K. Hallsten, R. Parkkola, T. Janatuinen, F. Lonnqvist, T. Viljanen, T. Ronnemaa, J. Knuuti, R. Huupponen, P. Lonnroth, et al. Differential Effects of Rosiglitazone and Metformin on Adipose Tissue Distribution and Glucose Uptake in Type 2 Diabetic Subjects Diabetes, February 1, 2003; 52(2): 283 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hallsten, K. A. Virtanen, F. Lonnqvist, H. Sipila, A. Oksanen, T. Viljanen, T. Ronnemaa, J. Viikari, J. Knuuti, and P. Nuutila Rosiglitazone but Not Metformin Enhances Insulin- and Exercise-Stimulated Skeletal Muscle Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes Diabetes, December 1, 2002; 51(12): 3479 - 3485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Meyer, K. Levin, T. Grimmsmann, N. Perwitz, A. Eirich, H. Beck-Nielsen, and H. H. Klein Troglitazone Treatment Increases Protein Kinase B Phosphorylation in Skeletal Muscle of Normoglycemic Subjects at Risk for the Development of Type 2 Diabetes Diabetes, September 1, 2002; 51(9): 2691 - 2697. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |